BP
ALLO icon

Ballentine Partners’s Allogene Therapeutics ALLO Stock Holding History

Ballentine Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.2K Sell
11,131
-3,739
-25% -$8.21K ﹤0.01% 1076
2026
Q1 		$36.3K Buy
14,870
+861
+6% +$1.73K ﹤0.01% 1005
2025
Q4 		$19.2K Buy
+14,009
New +$18.5K ﹤0.01% 1009

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ballentine Partners's ALLO Position: Q2 2026 in Review

Ballentine Partners reduced its Allogene Therapeutics (ALLO) stake by 25% in Q2 2026, selling an estimated $8.21K and leaving 11,131 shares worth $23.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1076.

Ballentine Partners first reported a position in ALLO in Q4 2025 and has held it in 3 quarters since. The position peaked at $36.3K in Q1 2026. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Ballentine Partners held 11,131 shares of Allogene Therapeutics worth $23.2K as of Q2 2026.
  • Ballentine Partners sold 3,739 Allogene Therapeutics shares in Q2 2026, an estimated $8.21K.
  • Allogene Therapeutics made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #1076 holding.
  • Ballentine Partners first reported a position in Allogene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Ballentine Partners's Allogene Therapeutics position peaked at $36.3K in Q1 2026.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.